Search Results - "Mulder, Emma R"

Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation by van Velden, Floris H. P., Kramer, Gerbrand M., Frings, Virginie, Nissen, Ida A., Mulder, Emma R., de Langen, Adrianus J., Hoekstra, Otto S., Smit, Egbert F., Boellaard, Ronald

“…Purpose To assess (1) the repeatability and (2) the impact of reconstruction methods and delineation on the repeatability of 105 radiomic features in…”
Get full text

How robust is the language architecture? The case of mood by Van Berkum, Jos J A, De Goede, Dieuwke, Van Alphen, Petra M, Mulder, Emma R, Kerstholt, José H

“…In neurocognitive research on language, the processing principles of the system at hand are usually assumed to be relatively invariant. However, research on…”
Get full text

Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer by van Helden, Erik J, Hoekstra, Otto S, Boellaard, Ronald, Roth, Chantal, Mulder, Emma R, Verheul, Henk M W, Menke-van der Houven van Oordt, C Willemien

“…The aim of this pilot study was to explore intrapatient mixed metabolic response and early 18F-FDG PET response evaluation using predefined quantification…”
Get full text

Hippocampal volume change measurement: Quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST by Mulder, Emma R., de Jong, Remko A., Knol, Dirk L., van Schijndel, Ronald A., Cover, Keith S., Visser, Pieter J., Barkhof, Frederik, Vrenken, Hugo

“…To measure hippocampal volume change in Alzheimer's disease (AD) or mild cognitive impairment (MCI), expert manual delineation is often used because of its…”
Get full text

Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease by Cover, Keith S, van Schijndel, Ronald A, Versteeg, Adriaan, Leung, Kelvin K, Mulder, Emma R, Jong, Remko A, Visser, Peter J, Redolfi, Alberto, Revillard, Jerome, Grenier, Baptiste, Manset, David, Damangir, Soheil, Bosco, Paolo, Vrenken, Hugo, van Dijk, Bob W, Frisoni, Giovanni B, Barkhof, Frederik

“…Abstract The purpose of this study is to assess the reproducibility of hippocampal atrophy rate measurements of commonly used fully-automated algorithms in…”
Get full text

89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding by van Brummelen, Emilie M.J., Huisman, Marc C., de Wit-van der Veen, Linda J., Nayak, Tapan K., Stokkel, Marcel P.M., Mulder, Emma R., Hoekstra, Otto S., Vugts, Danielle J., Van Dongen, Guus A.M.S., Verheul, Henk M., Evers, Stefan, Tessier, Jean J. L., Saro, Jose, Schellens, Jan H.M., Menke-van der Houven van Oordt, C. Willemien

“…Cergutuzumab amunaleukin (CEA-IL2v) is an immunocytokine directed against carcinoembryonic antigen (CEA) containing an IL2v-moiety with abolished IL-2 receptor…”
Get full text

89Zr-cetuximab PET imaging in patients with advanced colorectal cancer by Menke-van der Houven van Oordt, Catharina Willemien, Gootjes, Elske C, Huisman, Marc C, Vugts, Danielle J, Roth, Chantal, Luik, Anne Marije, Mulder, Emma R, Schuit, Robert C, Boellaard, Ronald, Hoekstra, Otto S, van Dongen, Guus Ams, Verheul, Henk M W

“…Monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) are used in the treatment of advanced colorectal cancer (mCRC). Approximately…”
Get full text

Early .sup.18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer by van Helden, Erik J, Hoekstra, Otto S, Boellaard, Ronald, Roth, Chantal, Mulder, Emma R, Verheul, Henk M. W, Menke-van der Houven van Oordt, C. Willemien

“…Objective The aim of this pilot study was to explore intrapatient mixed metabolic response and early .sup.18 F-FDG PET response evaluation using predefined…”
Get full text

ImmunoPET imaging with 89 Zr-cetuximab in patients with advanced colorectal cancer by Menke, Catharina Wilhelmina, Gootjes, Elske C., Huisman, Marc C., van Grieken, Nicole C.T., Vugts, Danielle J., Roth, Chantal, Mulder, Emma R., Schuit, Robert C., Boellaard, Ronald, Hoekstra, Otto S., Dongen, G.A.M.S. van, Verheul, Henk M.W.

“…Abstract only…”
Get full text

89 Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding by van Brummelen, Emilie M J, Huisman, Marc C, de Wit-van der Veen, Linda J, Nayak, Tapan K, Stokkel, Marcel P M, Mulder, Emma R, Hoekstra, Otto S, Vugts, Danielle J, Van Dongen, Guus A M S, Verheul, Henk M, Evers, Stefan, Tessier, Jean J L, Saro, Jose, Schellens, Jan H M, Menke-van der Houven van Oordt, C Willemien

“…Cergutuzumab amunaleukin (CEA-IL2v) is an immunocytokine directed against carcinoembryonic antigen (CEA) containing an IL2v-moiety with abolished IL-2 receptor…”
Get full text